Monoclonal Antibody

Monoclonal Antibody-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Biological products
May 25, 2017 - N°20170145114

There is disclosed antibody molecules containing at least one cdr derived from a mouse monoclonal antibody having specificity for human cd22. There is also disclosed a cdr grafted antibody wherein at least one of the cdrs is a modified cdr. Further disclosed are dna sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the ...
NEW Chimeric antigen receptor hcd87-car and applications thereof
May 25, 2017 - N°20170145106

The present invention relates to a cellular immunotherapy for treatment of tumors, particularly to a peptide of a chimeric antigen receptor hcd87-car and the applications thereof, the peptide of said antigen receptor being carried by a vector packaged in a lentivirus. The chimeric antigen receptor hcd87-car contains a fragment of anti cd87 monoclonal antibody hcd87scfv consisting of ...
NEW Cd33 specific chimeric antigen receptors for cancer immunotherapy
May 25, 2017 - N°20170145094

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a cd33 monoclonal antibody, conferring specific immunity against cd33 positive cells. The engineered immune cells endowed with such cars are particularly ...
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment for chronic lymphocytic leukemia (cll)
Xencor, Inc.
May 18, 2017 - N°20170137516

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody xmab5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level that achieves a total exposure to said patient measured ...
Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing
Xencor, Inc.
May 18, 2017 - N°20170137493

Wherein, t is a single chain variable portion fragment of a monoclonal antibody (scfv) directed to a target protein, polypeptide, or fragment thereof, which is highly expressed on cancer cells; e is two or more foreign immunogenic cd8+ t cell antigenic epitopes; c is a peptide or polypeptide fragment thereof, capable of being cleaved by a specific protease; and fc ...
Uses of monoclonal antibody 8h9
Sloan-kettering Institute For Cancer Research
May 11, 2017 - N°20170129964

This invention provides a composition comprising an effective amount of monoclonal antibody 8h9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8h9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8h9 comprising the complementary determining ...
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Oral composition of anti-tnf alpha antibodies
Laboratoire Français Du Fractionnement Et Des Biotechnologies
May 04, 2017 - N°20170121402

The present invention relates to a pharmaceutical composition for oral delivery, including an anti tumour necrosis factor alpha (tnfα) antibody, preferably a monoclonal antibody produced in the milk of a transgenic non-human animal, and which can be combined advantageously with caprylic acid, and is preferably in a form that is suitable for targeted release of the antibody in ...
Method for neutralizing hepatitis c virus, fully human monoclonal antibody against hepatitis c virus (variants), ...
Laboratoire Français Du Fractionnement Et Des Biotechnologies
May 04, 2017 - N°20170121390

The invention relates to the field of biotechnology, and specifically to methods and techniques for neutralizing the hepatitis c virus, and specifically to antibodies against the hepatitis c virus, and can be used in medicine, the pharmaceutical industry and related areas of science and technology. Proposed is the use of fully human monoclonal antibodies—ryb1, ryb2 and ryb3—...
Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
May 04, 2017 - N°20170119883

Methods, pharmaceutical compositions, and kits for treating a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a platinum agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof.
Combination therapies targeting tumor-associated stroma or tumor cells
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
May 04, 2017 - N°20170119882

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of an agent selected from the group consisting of an anti-angiogenic agent, a vascular disrupting agent (vda), and combinations thereof; and (b) a ...
Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
May 04, 2017 - N°20170119881

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a microtubule inhibitor; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody ...
One-step labeling of antibodies to high specific activity with actinium-225
Sloan-kettering Institute For Cancer Research
April 27, 2017 - N°20170112951

Provided herein is a one-step method for chelating actinium-225 to a construct comprising a chelator linked to a bio-molecule, such as, an antibody or monoclonal antibody, via a bifunctional ligand in, for example, a 3-arm configuration. Also provided are methods for increasing the radiochemical yield of an actinium-225-chelant-biomolecule complex and for producing a high specific activity actinium-225 complex. The ...
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
April 27, 2017 - N°20170112928

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a topoisomerase inhibitor; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody ...
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
April 27, 2017 - N°20170112926

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of an agent selected from an anti-metabolite agent or analog thereof and combinations thereof; and (b) a therapeutically effective amount of a monoclonal ...
Foxc1 antibodies and methods of their use
John Wayne Cancer Institute
April 20, 2017 - N°20170108500

In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human foxc1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that ...
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist ...
Bavarian Nordic A/s
April 20, 2017 - N°20170106065

The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with a monoclonal antibody against immune checkpoint molecule tim-3.
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
The United States Of America, As Represented By The Secretary, Department Of Health And Human
April 13, 2017 - N°20170101464

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment of the present invention, and (b) a therapeutically effective amount of a combination therapy including ...
Therapeutic agent for inflammatory disease
Josai University Corporation
April 06, 2017 - N°20170096478

The present invention relates to a therapeutic agent for inflammation in which histone is involved, the agent comprising a monoclonal antibody or an antigen binding fragment thereof which binds to a peptide consisting of an amino acid sequence represented by ssvlyggppsaa (seq id no:1) or a conjugate of the peptide and a pharmaceutically acceptable carrier.
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
The United States Of America, As Represented By The Secretary, Department Of
April 06, 2017 - N°20170095575

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a molecularly targeted agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal ...
Antibody formulation
Glaxosmithkline Intellectual Property Management Limited
April 06, 2017 - N°20170095555

The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent.
Feeding strategies and purification processes for monoclonal antibody production
Serum Institute Of India Private Limited
March 30, 2017 - N°20170088873

This invention provides an improved process for manufacturing a rabies monoclonal antibody (humab 17c7) that results in low osmolality, minimum secondary metabolites like ammonia and lactate, enhanced cell growth and productivity, minimum aggregation or degradation of monoclonal antibody during purification, thereby improving potency of monoclonal antibody (humab 17c7) as compared to human rabies immunoglobulin (hrig).